Aktis Oncology, Inc.

13 articles about Aktis Oncology, Inc.

• AKTIS ONCOLOGY TO PARTICIPATE IN THE TD COWEN 44TH ANNUAL HEALTHCARE CONFERENCE

  2/28/2024

  Aktis Oncology today announced that Matthew Roden , Ph.D., President and Chief Executive Officer, and Shulamit Ron-Bigger , Ph.D., Chief Operating Officer of Aktis Oncology, will participate in Investor meetings at the TD Cowen 44th Annual Healthcare Conference in Boston, Mass. on Monday, March 4, 2024.

• AKTIS ONCOLOGY TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

  1/3/2024

  Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.

• Aktis Oncology Expands Scientific Advisory Board to Advance Pipeline of Targeted Alpha Radiopharmaceuticals

  6/15/2023

  Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced the appointment of Germo Gericke, MD, to its Scientific Advisory Board.

• AKTIS ONCOLOGY TO PARTICIPATE IN JEFFERIES HEALTHCARE CONFERENCE

  6/6/2023

  Aktis Oncology today announced Matthew Roden , PhD, President and Chief Executive Officer will participate in the Jefferies Healthcare Conference in New York City , June 7-9.

• Aktis Oncology to Participate in 2023 Guggenheim Healthcare Talks: Radiopharmaceuticals Day

  5/12/2023

  Aktis Oncology announced Matthew Roden, PhD, President and Chief Executive Officer, and Shulamit Ron-Bigger, PhD, Chief Operating Officer, will participate in the 2023 Guggenheim Healthcare Talks: Radiopharmaceuticals Day, held on May 15 in New York City.

• AKTIS ONCOLOGY TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE

  3/6/2023

  Aktis Oncology today announced that company management of Aktis Oncology will participate in one-on-one investor meetings at Cowen's 43rd Annual Healthcare Conference in Boston, MA, on Wednesday, March 8, 2023.   

• Aktis Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced the company will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA, Jan. 9 – 12.

• AKTIS ONCOLOGY APPOINTS SHULAMIT RON-BIGGER AS CHIEF OPERATING OFFICER

  9/19/2022

  Aktis Oncology today announced the appointment of Shulamit Ron-Bigger, PhD, as Chief Operating Officer (COO).

• Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals

  8/25/2022

  Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced it has raised a Series A Extension financing of $84 million, bringing the total capital raised to date to $161 million.

• Aktis Oncology Announces Actinium-225 Supply Agreements with Leading Isotope Producers

  8/23/2022

  Aktis Oncology today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225.

• 

  BioSpace Movers & Shakers, Jan. 21

  1/21/2022

  Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. 

• Aktis Oncology Expands Leadership Team with Two Strategic Hires

  1/18/2022

  Aktis Oncology today announced the expansion of their leadership team and scientific capabilities through the appointments of Tyler Benedum , PhD, as Senior Vice President, Head of Chemistry, Manufacturing, and Controls (CMC), and Daša Lipovšek, PhD, as Vice President, Head of Lead Discovery.

• Aktis Oncology To Present At The 40th Annual J.P. Morgan Healthcare Conference

  1/6/2022

  Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers, announced the company will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference, taking place virtually, Jan. 9 - 12.